--- title: "Bragar Eagel & Squire, P.C.敦促 XPLR 基礎設施、Centene、Biohaven 或 Capricor 的投資者瞭解他們在集體訴訟中的權利" description: "Bragar Eagel & Squire, P.C. 正在敦促 XPLR Infrastructure、Centene、Biohaven 和 Capricor 的投資者查詢他們在正在進行的集體訴訟中的權利。這些訴訟指控公司在財務狀況和運營方面存在誤導性陳述和未披露關鍵信息。投資者有截止日期向法院申請擔任首席原告。與這些問題相關的公告後，股票價格顯著下跌，突顯了對股東的潛在影響" type: "news" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/251301038.md" published_at: "2025-08-02T16:05:32.000Z" --- # Bragar Eagel & Squire, P.C.敦促 XPLR 基礎設施、Centene、Biohaven 或 Capricor 的投資者瞭解他們在集體訴訟中的權利 > Bragar Eagel & Squire, P.C. 正在敦促 XPLR Infrastructure、Centene、Biohaven 和 Capricor 的投資者查詢他們在正在進行的集體訴訟中的權利。這些訴訟指控公司在財務狀況和運營方面存在誤導性陳述和未披露關鍵信息。投資者有截止日期向法院申請擔任首席原告。與這些問題相關的公告後，股票價格顯著下跌，突顯了對股東的潛在影響 **If you purchased or acquired securities in any of the above companies during their class period and would like to discuss your legal rights, call Bragar Eagel & Squire partner** **Brandon Walker** **or** **Marion Passmore** **directly at (212) 355-4648** NEW YORK, Aug. 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of XPLR Infrastructure, LP (NYSE: XIFR), Centene Corporation (NYSE:CNC), Biohaven Ltd. (NYSE:BHVN), and Capricor Therapeutics, Inc. (NASDAQ:CAPR). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. **XPLR Infrastructure, LP (NYSE: XIFR)** The *XPLR Infrastructure* class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) XPLR Infrastructure was struggling to maintain its operations as a yieldco; (ii) defendants temporarily relieved this issue by entering into certain financing arrangements while downplaying the attendant risks; (iii) XPLR Infrastructure could not resolve those financings before their maturity date without risking significant unitholder dilution; (iv) as a result, defendants planned to halt cash distributions to investors and instead redirect those funds to, among other things, resolve those financings; and (v) consequently, XPLR Infrastructure’s yieldco business model and distribution growth rate was unsustainable. The *XPLR Infrastructure* class action lawsuit further alleges that on January 28, 2025, XPLR Infrastructure announced that it would suspend entirely cash distributions to common unitholders and essentially abandon its yieldco model. On this news, the price of XPLR Infrastructure common units fell by nearly 35%, the complaint alleges. For more information on the XPLR Infrastructure lawsuit go to: https://bespc.com/cases/XIFR **Centene Corporation (NYSE:CNC)** According to the complaint, defendants created the false impression that they possessed reliable information pertaining to the Company’s projected revenue outlook and anticipated growth while also touting enrollment rates and low morbidity. In truth, Centene’s optimistic reports and promises regarding the Company’s inflated guidance fell short of reality when a preliminary analysis of over two-thirds of Centene’s marketplace share showed lower-than-anticipated enrollment and increased aggregate market morbidity. Plaintiff alleges that on July 1, 2025, Centene issued a press release withdrawing 2025 guidance. Specifically, following an analysis of the 2025 Health Insurance Marketplace, Centene’s overall market growth across 22 states, or 72% of the Company’s marketplace membership, was lower than expected. In pertinent part, the Company stated that this preliminary analysis resulted in a reduction of its previously issued guidance to approximately $1.8 billion or an adjusted diluted EPS of $2.75. On this news, Centene's common stock fell from %56.65 per share on July 1, 2025, to $44.78 per share on July 2, 2025, a decline of over 40%. For more information on the Centene lawsuit go to: https://bespc.com/cases/CNC **Biohaven Ltd. (NYSE:BHVN)** The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) troriluzole's regulatory prospects as a treatment for SCA, and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (2) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (3) all the foregoing, once revealed, was likely to have a significant negative impact on Biohaven's business and financial condition; and (4) as a result, Defendants' public statements were materially false and misleading at all relevant times. For more information on the Biohaven lawsuit go to: https://bespc.com/cases/BHVN **Capricor Therapeutics, Inc. (NASDAQ:CAPR)** According to the complaint, defendants provided investors with material information concerning Capricor’s lead cell therapy candidate drug deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Defendants’ statements included, among other things, Capricor’s ability to obtain a Biologics License Application (BLA) for deramiocel from the U.S. Food and Drug Administration (FDA). Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning its four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel. On July 11, 2025, Capricor issued a press release announcing it received a Complete Response Letter (CRL) from the FDA denying the BLA specifically citing it did not meet the statutory requirement for substantial evidence of effectiveness and the need for additional clinical data. Further, the CRL referenced outstanding items in the Chemistry, Manufacturing, and Controls section of the application. Following this news, the price of Capricor stock declined from $11.40 per share on July 10, 2025 to $7.64 per share on July 11, 2025. For more information on the Capricor lawsuit go to: https://bespc.com/cases/CAPR **About Bragar Eagel & Squire, P.C.:** Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. **Contact Information:** Bragar Eagel & Squire, P.C. Brandon Walker, Esq. Marion Passmore, Esq. (212) 355-4648 investigations@bespc.com www.bespc.com ### Related Stocks - [CAPR.US - Capricor治療](https://longbridge.com/zh-HK/quote/CAPR.US.md) - [CNC.US - 康西哥](https://longbridge.com/zh-HK/quote/CNC.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Health Net 和职业橄榄球名人堂在超级碗周期间表彰萨克拉门托社区，并激励当地青年 | 健康网与职业足球名人堂于 2 月 4 日共同在萨克拉门托社区举办了两场具有深远影响的活动，分别是 “致敬服务” 和 “强壮青年，强壮社区”。这些活动表彰了当地医疗保健领域的英雄，并通过 NFL 传奇球员和社区领袖的激励演讲激励了年轻人。“致 | [Link](https://longbridge.com/zh-HK/news/275263021.md) | | 揭开康西哥的神秘面纱：5 位分析师的深度见解 | Centene（纽约证券交易所代码：CNC）在过去三个月中获得了 5 位分析师的褒贬不一的评价，评级从看涨到看跌不等。12 个月的平均目标价为 43.6 美元，较之前的 39.40 美元有所上升，最高为 54.00 美元，最低为 35.00 | [Link](https://longbridge.com/zh-HK/news/275357293.md) | | Absolute Total Care 荣获 2025 年 Press Ganey 人类体验卓越巅峰奖® \| CNC 股票新闻 | Absolute Total Care 荣获 2025 年 Press Ganey 人类体验卓越奖®，因其在全国健康计划中会员体验排名前 5%。这一认可突显了该组织优先考虑会员声音并通过个性化沟通策略和主动参与提供卓越护理的承诺。该奖项反映 | [Link](https://longbridge.com/zh-HK/news/275359938.md) | | 西维斯 (CVS) 第四季度收益：有哪些预期 | CVS Health 将于本周二公布其第四季度财报。分析师预计收入将同比增长 6.1%，达到 1037 亿美元，调整后的每股收益为 1.00 美元。CVS Health 上季度的收入超出预期 4.1%。然而，该公司在过去两年中曾两次未能达到 | [Link](https://longbridge.com/zh-HK/news/275258196.md) | | 健康网和职业橄榄球名人堂在超级碗周期间表彰萨克拉门托社区并激励当地青年 \| CNC 股票新闻 | 健康网和职业足球名人堂在超级碗周期间于萨克拉门托举办了两场活动：“致敬服务” 和 “强壮青年，强大社区”。这些活动表彰了医疗保健英雄，并通过与职业足球传奇人物的激励演讲和活动赋能当地青年。萨克拉门托市市长凯文·麦卡蒂和 WellSpace | [Link](https://longbridge.com/zh-HK/news/275150829.md) | --- > **免責聲明**：本文內容僅供參考，不構成任何投資建議。